Neurocrine Biosciences (NBIX)
(Delayed Data from NSDQ)
$140.71 USD
+0.88 (0.63%)
Updated May 3, 2024 04:00 PM ET
After-Market: $140.73 +0.02 (0.01%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth B Momentum B VGM
Brokerage Reports
Neurocrine Biosciences, Inc. [NBIX]
Reports for Purchase
Showing records 1 - 20 ( 302 total )
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
Focusing on Importance of PK and Safety for Topline Data of 568¯Our Thoughts
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
Onward As NBIX Sets Stage With FY24 Guidance, Near-Term Crinecerfont Filing
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
Kickstart or False Start? What January Tells Us about Biotech Annual Returns
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
Neurocrine Shifts Focus Towards Neurology, Eyeing at Movement Disorder Diseases and Psychosis
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
If Cash Is King In Biotech, Pipelines Are The Queens
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
KOL Call Invite: Epilepsy KOL Check - AES Wrap and Thoughts Into 2024
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
HEALTHCARE - The Week Ahead in Life Sciences
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
Optimized Entry and Exit Levels for NBIX 112223
Provider: Stock Traders Daily
Analyst: Research Department
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
Setting Expectations For the NBI-921352 FOS Readout; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
3Q23 Commercial Preview: Some Fireworks Ahead, But Prereleases Steal Thunder
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
Crinecerfont Wins Over Androgens Across Patient Age Groups; Reiterate Buy and PT Up to $150
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
Pediatric Phase 3 CAHtalyst Offers Another Pipeline Win
Provider: Wedbush Securities Inc.
Analyst: CHICO L